Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2024-07-25 | Reverse | 1:10 |
| 2013-11-19 | Reverse | 1:2 |
Evogene Ltd. leverages AI and big data through its CPB platform to develop innovative products across agriculture, human health, and industrial sectors worldwide.
Evogene's proprietary generative AI platform accelerates the discovery and optimization of novel small molecules for pharma and agriculture, enhancing potency, success rates, and reducing development time and costs for partners.
In June 2025, Evogene announced the completion of its generative AI foundation model for small molecule design, developed in collaboration with Google Cloud. This news led to a dramatic surge in the company's stock price, with reports of it doubling in a single day, as it highlighted a significant technological milestone in the company's strategic shift towards AI-driven innovation in the pharmaceutical and agricultural sectors.
In 2025, Evogene undertook a significant strategic transformation to center its business on its proprietary 'ChemPass AI' platform for small molecule discovery in the pharmaceutical and agricultural sectors. This shift involved major restructuring, including significant workforce reductions, and the divestiture of its subsidiary Lavie Bio's main activities to ICL.
REHOVOT, Israel, Oct. 6, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneer in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it has entered into a comprehensive cooperation agreement (the "Agreement") with L.I.A.
Evogene (NASDAQ: EVGN - Get Free Report) and Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership. Institutional and Insider Ownership 10.4% of Evogene shares
Overall rating: C
| PEER | PRICE | |
|---|---|---|
 CING | $4.88 | COMPARE |
 DWTX | $1.44 | COMPARE |
 MRKR | $1.00 | COMPARE |
 COCP | $1.06 | COMPARE |
 AEON | $0.32 | COMPARE |
 CLRB | $1.44 | COMPARE |
 BOLT | $3.67 | COMPARE |
 IMNN | $1.07 | COMPARE |
